{
    "2020-01-27": [
        [
            {
                "time": "2018-03-15",
                "original_text": "US FDA approves only triple-combination tablet with JardianceÂ® for adults with type 2 diabetes",
                "features": {
                    "keywords": [
                        "FDA",
                        "approval",
                        "Jardiance",
                        "type 2 diabetes"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "Eli Lilly Trading Near Top Of Buy Zone With Earnings On Tap",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "trading",
                        "buy zone",
                        "earnings"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-20",
                "original_text": "Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "LLY",
                        "medical stocks",
                        "outpaced"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-02-01",
                "original_text": "Lilly (LLY) to Report Q4 Earnings: What's in the Cards?",
                "features": {
                    "keywords": [
                        "Lilly",
                        "LLY",
                        "Q4 earnings",
                        "report"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-03-25",
                "original_text": "Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Incyte",
                        "Phase 3",
                        "Baricitinib",
                        "atopic dermatitis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}